阿尔茨海默病治疗药物研究进展

被引：13

作者：

张倩 ^{[1
]}

李建涛 ^{[2
]}

宋春霞 ^{[1
]}

王凤山 ^{[3
]}

机构：

[1] 山东大学(威海)海洋学院

[2] 威海市立医院

[3] 山东大学药学院

来源：

中国老年学杂志 | 2015年 / 35卷 / 08期

关键词：

阿尔茨海默病; 免疫治疗剂; 钙离子拮抗剂;

D O I：

暂无

中图分类号：

R749.16 [];

学科分类号：

100203 ;

摘要：

<正>目前全球约3 600万人患有阿尔茨海默病(AD),在欧美主要城市人群中AD是仅次于癌症的第二大忧患,而在我国1984～2004年60岁以上人口发病率为1.6%〔1〕,我国AD患者总数已超过500万〔2〕。目前对于AD仍然缺乏特异性的治疗方法,研究重点仍是针对AD的各相关症状的药物。1胆碱酯酶抑制剂(CHEI)研究表明AD患者的大脑皮层、海马结构和边缘系统中胆

引用

页码：2282 / 2285

页数：4

共 20 条

[11]

Effect of Vitamin E Administration on the Elevated Oxygen Stress and the Telomeric and Subtelomeric Status in Alzheimer’s Disease[J] . Guan, Jing-zhi,Guan, Wei-ping,Maeda, Toyoki,Makino, Naoki.Gerontology . 2011 (1)

[12]

A phase 2 randomized trial of ELND005, scyllo-inositol, in mild to moderate Alzheimer disease[J] . S. Salloway,R. Sperling,R. Keren,A.P. Porsteinsson,C.H. van Dyck,P.N. Tariot,S. Gilman,D. Arnold,S. Abushakra,C. Hernandez,G. Crans,E. Liang,G. Quinn,M. Bairu,A. Pastrak,J.M. Cedarbaum.Neurology . 2011 (13)

[13]

The pharmacology of selegiline[J] . Kálmán Magyar.International Review of Neurobiology . 2011

[14] A phase II trial of huperzine A in mild to moderate Alzheimer disease [J].

Rafii, M. S. ;

Walsh, S. ;

Little, J. T. ;

Behan, K. ;

Reynolds, B. ;

Ward, C. ;

Jin, S. ;

Thomas, R. ;

Aisen, P. S. .

NEUROLOGY, 2011, 76 (16) :1389-1394

[15]

Tramiprosate in mild-to-moderate Alzheimer’s disease - a randomized, double-blind, placebo-controlled, multi-centre study （the Alphase Study）. PS Aisen,S Gauthier,SH Ferris,D Saumier,D Haine,D Garceau,A Duong,J Suhy,J Oh,WC Lau,J Sampalis. Archives of medical science : AMS . 2011

[16]

Effectiveness and tolerability of high-dose （23 mg/d） versus standard-dose （10 mg/d） donepezil in moderate to severe Alzheimer’s disease: A 24-week, randomized, double-blind study[J] . Martin R. Farlow,Stephen Salloway,Pierre N. Tariot,Jane Yardley,Margaret L. Moline,Qin Wang,Elimor Brand-Schieber,Heng Zou,Timothy Hsu,Andrew Satlin.Clinical Therapeutics . 2010 (7)

[17] Small molecule β-amyloid inhibitors that stabilize protofibrillar structures in vitro improve cognition and pathology in a mouse model of Alzheimer's disease [J].

Hawkes, Cheryl A. ;

Deng, Le-Hua ;

Shaw, James E. ;

Nitz, Mark ;

McLaurin, JoAnne .

EUROPEAN JOURNAL OF NEUROSCIENCE, 2010, 31 (02) :203-213

[18]

Anti-Amyloid-β Immunotherapy in Alzheimer’s Disease: ACC-001 Clinical Trials Are Ongoing[J] . J. Michael Ryan,Michael Grundman.Journal of Alzheimer’s Disease . 2009 (2)

[19] Orally available compound prevents deficits in memory caused by the Alzheimer amyloid-β oligomers [J].

Townsend, Matthew ;

Cleary, James P. ;

Mehta, Tapan ;

Hofmeister, Jacki ;

Lesne, Sylvain ;

O'Hare, Eugene ;

Walsh, Dominic M. ;

Selkoe, Dennis J. .

ANNALS OF NEUROLOGY, 2006, 60 (06) :668-676

[20]

Pharmacotherapeutic approaches to the prevention of Alzheimer’s disease[J] . John B. Standridge.American Journal of Geriatric Pharmacotherapy . 2004 (2)

← 1 2 →